| GR00016-A | 5888 | 5888 | RAD51 | np | 1.9 | none | | no | | Wnt/beta-catenin pathway regulation | Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. | James et al. | 2009 | 19471023 | Cell line | RKO | Wnt/beta-catenin pathway reporter | Luminescence | rp | Selected genes | siRNA | Z-score | > 2 | | GR00053-A | 5888 | NM_002875 | RAD51 | np | sp | none | | no | | Genome stability | A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. | Paulsen et al. | 2009 | 19647519 | Cell line | HeLa | gamma-H2AX phosphorylation and DNA content | Fluorescence | siARRAY human genome siRNA library | Genome-wide | siRNA | p-value | Complex criteria | Confidence groupings from 4 to 1 (highest level of confidence in group 4) | GR00054-A | 5888 | NM_002875 | RAD51 | np | 0.92 | none | | no | | Combinatorial effect with paclitaxel | Synthetic lethal screen identification of chemosensitizer loci in cancer cells. | Whitehurst et al. | 2007 | 17429401 | Cell line | NCI-H1155 | Viability (synthetic lethal) | ATP level | # G-005000-01 | Genome-wide | siRNA | Paclitaxel/control ratio | Complex criteria | Additional information about 87 high-confidence hits | GR00056-A | 5888 | NM_002875 | RAD51 | np | 1.133 | none | | no | | Melanogenesis | Genome-wide siRNA-based functional genomics of pigmentation identifies novel genes and pathways that impact melanogenesis in human cells. | Ganesan et al. | 2008 | 19057677 | Cell line | MNT-1 | Melanin protein expression and viability | Absorbance and luminescence | rp | Genome-wide | siRNA | Normalized absorbance ratio | > 2 standard deviations below mean | Additional information about a secondary screen (retest to determine false-positive rate) | GR00057-A-1 | 5888 | NM_002875 | RAD51 | M-003530-03 | 2.26 | none | | no | | Wnt/beta-catenin pathway regulation (1) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Z-score | > 4 | Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00057-A-2 | 5888 | NM_002875 | RAD51 | M-003530-03 | sp | none | | no | | Wnt/beta-catenin pathway regulation (2) | A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. | Tang et al. | 2008 | 18621708 | Cell line | HeLa | Wnt pathway reporter | Luminescence | Human siArray siRNA library | Genome-wide | siRNA | Complex, SP | Complex criteria | Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). | GR00095-A | 5888 | NM_002875 | RAD51 | np | np | none | | | | p53 pathway components | A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Berns et al. | 2004 | 15042092 | Cell line | BJ-TERT-tsLT fibroblasts | Proliferation | Colony-forming cell assay | Nki library | Genome-wide | shRNA | np | np | | GR00098-A-1 | 5888 | ENSG00000051180 | RAD51 | ENSG00000051180 | sp | none | | no | | Cell division (1) | Genome-scale RNAi profiling of cell division in human tissue culture cells. | Kittler et al. | 2007 | 17994010 | Cell line | HeLa | Cell number and DNA content | Laser scanning cytometry | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00101-A-1 | 5888 | NM_002875 | RAD51 | np | np | Synthetic lethal with cisplatin | | yes | | Combinatorial effect with anticancer drugs (1): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | log2 ratio | 2 standard deviations from mean ratio | Additional information about the primary genome-wide screen | GR00101-A-2 | 5888 | NM_002875 | RAD51 | np | np | none | | yes | | Combinatorial effect with anticancer drugs (2): gemcitabine | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | log2 ratio | 2 standard deviations from mean ratio | Additional information about the primary genome-wide screen | GR00101-A-3 | 5888 | NM_002875 | RAD51 | np | np | none | | yes | | Combinatorial effect with anticancer drugs (3): paclitaxel | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | log2 ratio | 1.7 standard deviations from mean ratio | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | siRNA 1 | 1.9 | none | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | siRNA 3 | 4.7 | Decreased viability with cisplatin | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | siRNA 1 - chem. modified | 5.7 | Decreased viability with cisplatin | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | siRNA 2 | 7.1 | Decreased viability with cisplatin | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | siRNA 2 - chem. modified | 7.2 | Decreased viability with cisplatin | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | np | 7.6 | Decreased viability with cisplatin | | yes | validated: 2 individual siRNAs at 2 fold EC50 shift or greater | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | np, pool chem. modified | 7.7 | Decreased viability with cisplatin | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00101-A-4 | 5888 | NM_002875 | RAD51 | siRNA 3 - chem. modified | 8.4 | Decreased viability with cisplatin | | yes | | Combinatorial effect with anticancer drugs (4): cisplatin | Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. | Bartz et al. | 2006 | 17000754 | Cell line | HeLa | Viability (synthetic lethal) | Alamar Blue | rp | Selected genes | siRNA | Fold EC50 shift | > | Additional information about the primary genome-wide screen | GR00103-A-0 | 5888 | | RAD51 | v2HS_171183 | -1.03 | Increased cell death HMECs cells | | no | | Cell viability | Cancer proliferation gene discovery through functional genomics. | Schlabach et al. | 2008 | 18239126 | Cell line | DLD-1, HCT116; HCC1954; HMECs (mammary epithelia cells) | Cell viability | Micoarray hybridization | shRNA-mir (G. Hannon) | | shRNA | log ratio | < | | GR00103-A-0 | 5888 | | RAD51 | v2HS_171184 | -1.03 | Increased cell death in HCT116 cells | | no | | Cell viability | Cancer proliferation gene discovery through functional genomics. | Schlabach et al. | 2008 | 18239126 | Cell line | DLD-1, HCT116; HCC1954; HMECs (mammary epithelia cells) | Cell viability | Micoarray hybridization | shRNA-mir (G. Hannon) | | shRNA | log ratio | < | | GR00103-A-0 | 5888 | | RAD51 | v2HS_218486 | -1.42 | Increased cell death HMECs cells | | no | | Cell viability | Cancer proliferation gene discovery through functional genomics. | Schlabach et al. | 2008 | 18239126 | Cell line | DLD-1, HCT116; HCC1954; HMECs (mammary epithelia cells) | Cell viability | Micoarray hybridization | shRNA-mir (G. Hannon) | | shRNA | log ratio | < | | GR00106-A-0 | 5888 | | RAD51 | np | 12 | Decreased viability | | no | | Cell viability | Highly parallel identification of essential genes in cancer cells. | Luo et al. | 2008 | 19091943 | Cell line | 12 cancer cell lines | Cell viability | Micoarray hybridization | TRC shRNA library | | shRNA | Essentiality | > | | GR00123-A | 5888 | NM_002875 | RAD51 | 141472, 141471, 141473, 141873, 141871, 141872 | np | none | | | | Combinatorial effect with nutlin-3 | An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors | Brummelkamp et al. | 2006 | 16474381 | Cell line | MCF-7 | Viability | Fluoresence | Nki library | Genome-wide | shRNA | log2 ratio | np | | GR00133-A-1 | 5888 | 5888 | RAD51 | np | -0.027745 | none | | no | | Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) | RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. | Misselwitz et al. | 2011 | 21407211 | Cell line | HeLa | Gentamycin protection invasion assay | Fluorescence | Druggable genome library V2.0 | Druggable genes | siRNA | log2 median | Complex criteria | | GR00149-A-1 | 5888 | 5888 | RAD51 | 4467 | -60.27 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 4467 | 6.94 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 121401 | -18.43 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 121401 | -21.93 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 121402 | -40.49 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 121402 | -33.72 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 121403 | 108.15 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00149-A-1 | 5888 | 5888 | RAD51 | 121403 | 69.75 | none | | no | | Ciliogenesis and cilium length (1) | Functional genomic screen for modulators of ciliogenesis and cilium length. | Kim et al. | 2010 | 20393563 | Cell line | htRPE | Smoothed protein expression | Fluorescence | Human druggable genome siRNA library V3.1 | Druggable genes | siRNA | Normalized percent inhibition | > 1.5 OR < -1.5 standard deviations from mean | | GR00151-A-1 | 5888 | ENSG00000051180 | RAD51 | np | -5.196 | Decreased homologous recombination repair frequency | | yes | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. | Słabicki et al. | 2010 | 20613862 | Cell line | HeLa | (HR-DSBR) DR-GFP reporter | Flow cytometry | Custom-made | Genome-wide | esiRNA | Z-score | < -2 OR > 2 | | GR00151-A-2 | 5888 | ENSG00000051180 | RAD51 | RAD51 esiRNA 1 | < -4 | Decreased homologous recombination repair frequency | | yes | | Homologous recombination DNA double-strand break repair (HR-DSBR) (2) | A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. | Słabicki et al. | 2010 | 20613862 | Cell line | HeLa | (HR-DSBR) DR-GFP reporter | Flow cytometry | Custom-made | Selected genes | esiRNA | Z-score | Complex criteria | | GR00151-A-2 | 5888 | ENSG00000051180 | RAD51 | RAD51 esiRNA 2 | < -4 | Decreased homologous recombination repair frequency | | yes | | Homologous recombination DNA double-strand break repair (HR-DSBR) (2) | A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. | Słabicki et al. | 2010 | 20613862 | Cell line | HeLa | (HR-DSBR) DR-GFP reporter | Flow cytometry | Custom-made | Selected genes | esiRNA | Z-score | Complex criteria | | GR00180-A-1 | 5888 | 5888 | RAD51 | PL-50015 | 0.146 | none | | no | | Hepatitis C virus replication (1) | A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. | Tai et al. | 2009 | 19286138 | Cell line | Huh7/Rep-Feo | HCV replicon RNA copy number | Luminescence | siARRAY Human Genome siRNA Library | Genome-wide | siRNA | q-value | Complex criteria | | GR00184-A-1 | 5888 | NM_002875 | RAD51 | M-003530-03 | -1.15149654754576 | none | | no | top 200 hESCs survivability candidate gene (nuclei number reduction) | Self-renewal and pluripotency in human embryonic stem cells (1) | A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. | Chia et al. | 2010 | 20953172 | Cell line | hESC H1 | POU5F1 protein expression | Fluorescence | SMARTpool siRNA library | Genome-wide | siRNA | Z-score | < -2 | | GR00196-A-1 | 5888 | ENSG00000051180 | | np | sp | Decreased viability of wild-type and TP53 knockout cells, decreased TP53 protein expression ratio (wild-type / TP53 knockout cells) | | yes | viability Z-score < -2 | TP53 interactions (1) | A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. | Krastev et al. | 2011 | 21642980 | Cell line | HCT116 ( wildtype and TP53 knockout) | TP53 protein expression and viability | Fluorescence | rp | Genome-wide | esiRNA | Complex, sp | Complex criteria | | GR00197-A-1 | 5888 | 5888 | RAD51 | M-003530-03 | 1.772521695 | none | | no | | Human papillomavirus oncogene expression regulation (1) | Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. | Smith et al. | 2010 | 20133580 | Cell line | C33A/BE2/18LCR c4 | HPV18 LCR reporter activity | Luminescence | Human siGENOME SMARTpool library | Genome-wide | siRNA | Z-score | > | Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 | | 5888 | | RAD51 | np | np | Decreased viability in ovarian lineage | | no | ovarian: no filter, 2nd best | | | | | | | | | | | | | | | | GR00236-A-1 | 5888 | 5888 | RAD51 | M-003530-03 | 0.10919222065068 | Decreased homologous recombination repair frequency | | yes | | Homologous recombination DNA double-strand break repair (HR-DSBR) (1) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Human siGENOME siRNA (G-005000-05) | Genome-wide | siRNA | Relative HR ratio | < ~0.4 OR > 1.88 | Cutoff values correspond 2 standard deviations from the screen-wide mean | | 5888 | 5888 | RAD51 | D-003530-02 | 1.45 | none | | yes | | | | | | | | | | | | | | | | | | 5888 | 5888 | RAD51 | D-003530-05 | 0.17 | Decreased homologous recombination repair frequency | | yes | strong cutoff | | | | | | | | | | | | | | | | | 5888 | 5888 | RAD51 | D-003530-07 | 0.03 | Decreased homologous recombination repair frequency | | yes | strong cutoff | | | | | | | | | | | | | | | | | 5888 | 5888 | RAD51 | D-003530-08 | 0.11 | Decreased homologous recombination repair frequency | | yes | strong cutoff, siRNA has 7mer antisense seed(s) matching to human RAD51 3'UTR | | | | | | | | | | | | | | | | GR00236-A-3 | 5888 | 5888 | RAD51 | s11734 | 0.1 | Decreased homologous recombination repair frequency | | yes | strong cutoff | Homologous recombination DNA double-strand break repair (HR-DSBR) (3) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Silencer Select | Selected genes | siRNA | Relative HR ratio | Strong: < ~0.4; weak: < ~0.59 | Cutoff values correspond 2 standard deviations from the screen-wide mean (strong) or 1.5 SD (weak) | GR00236-A-3 | 5888 | 5888 | RAD51 | s11735 | 0.38 | Decreased homologous recombination repair frequency | | yes | strong cutoff | Homologous recombination DNA double-strand break repair (HR-DSBR) (3) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Silencer Select | Selected genes | siRNA | Relative HR ratio | Strong: < ~0.4; weak: < ~0.59 | Cutoff values correspond 2 standard deviations from the screen-wide mean (strong) or 1.5 SD (weak) | GR00236-A-3 | 5888 | 5888 | RAD51 | s11736 | 0.06 | Decreased homologous recombination repair frequency | | yes | strong cutoff | Homologous recombination DNA double-strand break repair (HR-DSBR) (3) | A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. | Adamson et al. | 2012 | 22344029 | Cell line | DR-U2OS | (HR-DSBR) DR-GFP reporter and DNA content | Fluorescence | Silencer Select | Selected genes | siRNA | Relative HR ratio | Strong: < ~0.4; weak: < ~0.59 | Cutoff values correspond 2 standard deviations from the screen-wide mean (strong) or 1.5 SD (weak) | GR00240-S-1 | 5888 | NM_002875 | RAD51 | M-003530-03 | 0.74 | none | | yes | | TRAIL-induced apoptosis (1) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Z-score | > 4 | Author-submitted data | GR00240-S-2 | 5888 | NM_002875 | RAD51 | M-003530-03 | -0.81 | none | | no | Z-score -0.072 | TRAIL-induced apoptosis (2) | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. | Kranz and Boutros | 2014 | 24442637 | Cell line | U251MG | Viability (synthetic lethal) | Luminescence | SMART-pool siRNA | Genome-wide | siRNA | Differential score | > 3.6 AND viability Z-score < 4 | Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. | GR00242-A-1 | 5888 | NM_002875 | RAD51 | np | sp | none | | no | | Selective autophagy regulation (1) | Image-based genome-wide siRNA screen identifies selective autophagy factors. | Orvedahl et al. | 2011 | 22020285 | Cell line | HeLa/GFP-LC3 | Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression | Fluorescence | siGenome | Genome-wide | siRNA | Z-score | Complex criteria | | GR00246-A | 5888 | | RAD51 | np | np | none | | no | | Telomere protection | A siRNA-based screen for genes involved in chromosome end protection. | Lackner et al. | 2011 | 21760879 | Cell line | HeLa | Telomere dysfunction-induced foci (TIF) formation (53BP1 protein expression, FITC-TelC and DNA content) | Fluorescence | siGENOME | Selected genes | siRNA | Number of TIFs | > | HeLa 1.2.11 cells used | GR00247-A-1 | 5888 | | RAD51 | np | sp | none | | | rank: 9591 | Regulation of FOXO1 nuclear localization (1) | Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. | Senapedis et al. | 2011 | 21460183 | Cell line | U2OS | EGFP-FOXO1a protein expression and DNA content | Fluorescence | Human Genome library | Genome-wide | siRNA | Complex, sp | Complex criteria | | GR00249-S | 5888 | 5888 | RAD51 | J-003530-09 | -0.22847 | none | | no | number of cells compared to control (%): 77.05 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5888 | 5888 | RAD51 | M-003530-04 | -2.46466 | Decreased viability | | no | number of cells compared to control (%): 27.01 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5888 | 5888 | RAD51 | s11734 | 0.88063 | none | | no | number of cells compared to control (%): 73.86 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5888 | 5888 | RAD51 | s11735 | -0.484 | none | | no | number of cells compared to control (%): 72.22 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00249-S | 5888 | 5888 | RAD51 | s11736 | 0.80887 | none | | no | number of cells compared to control (%): 70.85 | Vaccinia virus (VACV) infection | Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. | Sivan et al. | 2013 | 23401514 | Cell line | HeLa | Vaccinia virus VACV IHD-J/GFP protein expression and DNA content | Fluorescence | Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus | Genome-wide | siRNA | Z-score | > | Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. | GR00250-A-1 | 5888 | 5888 | RAD51 | M-003530-03 | sp | none | | | duplicate screen, sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (1) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Genome-wide | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5888 | 5888 | RAD51 | D-003530-02 | sp | none | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5888 | 5888 | RAD51 | D-003530-05 | sp | none | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5888 | 5888 | RAD51 | D-003530-07 | sp | none | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-2 | 5888 | 5888 | RAD51 | D-003530-08 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | sextuplicate screen | Combinatorial effect with MLN4924, a NAE inhibitor (2) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | A375 | Viability (synthetic lethal) | Luminescence | np | Selected genes | siRNA | Complex, sp | Complex criteria | Phenotypes for 650 nmol/L MLN4924. Additional information about screens with 250 nmol/L MLN4924. | GR00250-A-3 | 5888 | 5888 | RAD51 | D-003530-02 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 91 nM MLN4924; set: 320DDR; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5888 | 5888 | RAD51 | D-003530-05 | sp | none | | | 91 nM MLN4924; set: 320DDR; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5888 | 5888 | RAD51 | D-003530-07 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 91 nM MLN4924; set: 320DDR; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00250-A-3 | 5888 | 5888 | RAD51 | D-003530-08 | sp | Increased viability with MLN4924 (a NAE inhibitor) | | | 91 nM MLN4924; set: 320DDR; final hit | Combinatorial effect with MLN4924, a NAE inhibitor (3) | Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. | Blank et al. | 2013 | 23100467 | Cell line | HCT116 | Viability (synthetic lethal) | Luminescence | np | Selected and random genes | siRNA | Complex, sp | Complex criteria | | GR00251-A-1 | 5888 | | RAD51 | np | -1.5 | Decreased shRNA abundance | | | | Non-small cell lung cancer (NSCLC) cytotoxicity (1) | Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. | Cron et al. | 2013 | 24040035 | Cell line | A549 | shRNA abundance | Microarray | np | Genome-wide | shRNA | Complex, sp | Complex criteria | All listed genes are final hits. Final hit: > | GR00251-A-2 | 5888 | | RAD51 | np | -1 | Decreased shRNA abundance | | | | Non-small cell lung cancer (NSCLC) cytotoxicity (2) | Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. | Cron et al. | 2013 | 24040035 | Cell line | NCI-H460 | shRNA abundance | Microarray | np | Genome-wide | shRNA | Complex, sp | Complex criteria | All listed genes are final hits. Final hit: > | GR00253-A | 5888 | NM_002875 | RAD51 | np | -0.735 | none | | | | hepcidin regulation | Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. | Mleczko-Sanecka et al. | 2014 | 24385536 | Cell line | Huh7 | hepcidin::fluc mRNA expression | Luminescence | siGenome siARRAY SMARTpool | Genome-wide | siRNA | Z-score | > | Cutoff < | GR00255-A-1 | 5888 | 5888 | RAD51 | TRCN0000018875, TRCN0000018876, TRCN0000018877, TRCN0000018878, TRCN0000018879 | -0.939357902 | none | | | | Negative genetic interactions (1) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-2 | 5888 | 5888 | RAD51 | TRCN0000018875, TRCN0000018876, TRCN0000018877, TRCN0000018878, TRCN0000018879 | 1.069456485 | none | | | | Negative genetic interactions (2) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.0 | HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-3 | 5888 | 5888 | RAD51 | TRCN0000018875, TRCN0000018876, TRCN0000018877, TRCN0000018878, TRCN0000018879 | -0.535050283 | none | | | | Negative genetic interactions (3) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-4 | 5888 | 5888 | RAD51 | TRCN0000018875, TRCN0000018876, TRCN0000018877, TRCN0000018878, TRCN0000018879 | 0.127178174 | none | | | | Negative genetic interactions (4) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -1.2 | HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00255-A-5 | 5888 | 5888 | RAD51 | TRCN0000018875, TRCN0000018876, TRCN0000018877, TRCN0000018878, TRCN0000018879 | -0.88438937 | Negative genetic interaction between KRASG13D/+ and KRAS+/- | | | | Negative genetic interactions (5) | A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. | Vizeacoumar et al. | 2013 | 24104479 | Cell line | HCT116 | shRNA abundance | Microarray | np | Genome-wide | shRNA | differential Gene Activity Ranking Profile (dGARP) | < -0.8 | HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) | GR00293-A | 5888 | | RAD51 | np | -0.013 | none | | | | Combinatorial effect with paclitaxel | Mechanisms Promoting Escape from Mitotic Stress−Induced Tumor Cell Death | Sinnott et al. | 2014 | 24860162 | Cell line | HCC366 | Viability | Luminescence | Thermo-Fisher | Genome-wide | siRNA | Z-score | < -2.5 | Final hits according to the author are indicated in the comment. | GR00300-A | 5888 | | RAD51 | TRCN0000018875, TRCN0000018876, TRCN0000018877, TRCN0000018878, TRCN0000018879 | 0 | none | | | | Combinatorial effect with RAF inhibitor PLX4720 | A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. | Whittaker et al. | 2013 | 23288408 | Cell line | A375 | shRNA abundance | Sequencing | TRC | Genome-wide | shRNA | Number of shRNAs ranked Top1000 | > 2 | The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. | GR00303-A | 5888 | NM_002875 | RAD51 | np | -6.45 | Decreased cell number | | | | Clear cell renal cell carcinoma (ccRCC) survival regulation | Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target | Gerlinger et al. | 2012 | 22362593 | Cell line | VHL-deficient RCC4 | Proliferation and Viability | Fluorescence | np | Genome-wide | siRNA | Z-score | < | In the phenotype data duplicates were in the original document, which have been removed. | GR00310-A-1 | 5888 | 5888 | RAD51 | np | 1.89 | none | | | | Sindbis virus (SINV) infection (1) | Genome-Wide RNAi Screen Identifies Novel Host Proteins Required for Alphavirus Entry | Ooi et al. | 2013 | 24367265 | Cell line | U2OS | Sindbis virus (SINV) reporter | Luminescence | Ambion Silencer V3 | Genome-wide | siRNA | Z-score | < -3 OR > 2 | | | 5888 | 5888 | RAD51 | np | 75.3 | Inconclusive | | | 48,2% viability | | | | | | | | | | | | | | | | GR00313-A | 5888 | NM_002875, NM_133487 | RAD51 | np | -1.89 | none | | | | TNF-alpha pathway regulation | A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. | Nickles et al. | 2012 | 22733992 | Cell line | HEK293T | NFkappaB pathway reporter | Luminescence | Qiagen | Genome-wide | siRNA | Z-score | < | Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. | GR00318-A | 5888 | 5888 | RAD51 | np | 1.515 | none | | | siRNA set: druggable genome | Huntingtin toxicity | A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease | Miller et al. | 2012 | 23209424 | Cell line | HEK293T | Caspase 3/7 activity | Fluorescence | Dharmacon | Selected genes | siRNA | Sum of normalized caspase 3/7 activity mean and standard error | < 0.683 | HEK293T cells were cotransfected with mutant Huntingtin fused to GFP (Htt1-558141Q-GFP). | GR00343-S | 5888 | 5888 | RAD51 | TRCN0000018876 | -2.5625 | shRNA abundance <= 25% | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 5888 | 5888 | RAD51 | TRCN0000018877 | 0.32250000000000156 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 5888 | 5888 | RAD51 | TRCN0000018875 | 0.9175000000000004 | none | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | GR00343-S | 5888 | 5888 | RAD51 | TRCN0000018879 | -3.6500000000000004 | shRNA abundance <= 25% | | | | Lentiviral shRNA "Achilles Heel" screen | Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia | Cole et al. | 2015 | 26058080 | Cell line | K562 | shRNA abundance | Fluorescence | Lentiviral shRNA library | Genome-wide | shRNA | Log2 ratio | < | Comparison of day 21 vs. day 0 abundance data | | 5888 | NM_002875 | RAD51 | M-003530-03 | np | none | | | | | | | | | | | | | | | | | | | | 5888 | NM_002875 | RAD51 | M-003530-03 | 3.52 | Decreased infection with West Nile virus (WNV) | | | 4.73 | | | | | | | | | | | | | | | | | 5888 | RAD51 | NM_002875 | D-003530-07 | 2.9 | Decreased West Nile virus (WNV) infection | | | 3.87 | | | | | | | | | | | | | | | | | 5888 | RAD51 | NM_002875 | D-003530-02 | 3.8 | Decreased West Nile virus (WNV) infection | | | 423 | | | | | | | | | | | | | | | | GR00362-A | 5888 | 5888 | RAD51 | np | np | Synthetic lethal with vaccinia virus (VACV) infection | | | | Vaccinia virus (VACV) replication | A loss of function analysis of host factors influencing Vaccina virus replication by RNA interference | Beard et al. | 2014 | 2401222 | Cell line | HeLa | VACV-A5eGFP expression | Fluorescence | SMARTpools, Dharmacon | Genome-wide | siRNA | Z-score | < | Genes were prescreened for viability, those declared as lethal were not screened for fluorescence. | | 5888 | 5888 | RAD51 | | -0.009999999999999953 | none | | | | | | | | | | | | | | | | | | | GR00371-A-1 | 5888 | 5888 | RAD51 | | -0.503467843318 | none | | | Ambion | Nanog expression in absence of bFGF and TGFbeta | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-2 | 5888 | RAD51 | 5888 | | -0.365579447365 | none | | | Ambion | Nanog expression in presence of TGFbeta inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-3 | 5888 | 5888 | RAD51 | | -0.370890025572 | none | | | Ambion | Nanog expression in presence of MEK inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-4 | 5888 | 5888 | RAD51 | | 0.28179964481 | none | | | Ambion | Nanog expression in presence of PI3K inhibitor | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00371-A-5 | 5888 | 5888 | RAD51 | | -0.815879615542 | none | | | Ambion | Nanog expression in presence of retinoic acid | Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways | Gonzales et al. | 2015 | 26232226 | Cell line | NANOG-GFP H1 hESC | NANOG expression | Fluorescence | Dharmacon and Ambion | Selected genes | siRNA | Z-score | >1,25 OR >1,5 [in at least two replicates] | Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. | GR00376-A-1 | 5888 | 5888 | RAD51 | | 0.386076103 | none | | | | Mitigators of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID | GR00376-A-2 | 5888 | 5888 | RAD51 | | 0.265115069 | none | | | | Sensitizers of SS1P-induced immunotoxicity | Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity | Pasetto et al. | 2015 | 25713356 | Cell line | KB cells | Viability | Luminescence | Ambion Silencer Select Version 4 | Genome-wide | siRNA | RSA P-value | <0.001 | SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID | GR00378-A | 5888 | | RAD51 | | -1.752482199 | none | | | | Poliovirus vaccine production | Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game | van der Sanden et al. | 2015 | 26581994 | Cell line | HEp-2C | Infection with Attenuated Poliovirus | ELISA | Dharmacon | Genome-wide | siRNA | Z-score | > | For infection, a single lot of the attenuated Sabin type 2 poliovirus was used for the screen. Gene IDs were not provided, only the gene name/symbol | | 5888 | NM_002875 | RAD51 | | 25.329 | none | | | | | | | | | | | | | | | | | | | GR00386-A-1 | 5888 | 5888 | RAD51 | | 45.1761224064321 | Decreased viability | | | | NOD2 stimulation by MDP | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | Viability | Luminescence | Dharmacon | Genome-wide | siRNA | Percentage growth | Decreased: <70, increased: >120 | Reagent IDs not provided | GR00386-A-2 | 5888 | 5888 | RAD51 | | -43.9 | none | | | | MDP-induced IL-8 secretion | A genome-wide small interfering RNA (siRNA) screen reveals nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. | Warner et al. | 2014 | 25170077 | Cell line | HEK293 stably expressing NOD2 | IL-8 secretion | ELISA | Dharmacon | Genome-wide | siRNA | Percent inhibition of IL-8 secretion | Increased: <-300, Decreased: >60 | Concentration of IL-8 was measured from cell supernatants by sandwich ELISA. IL-8 values (pg/ml) were normalized to IL-8 secreted in cells treated with RIPK2-specific siRNA (100% inhibition) and non-targeting siRNA (0% inhibition). Secondary validating screen assessed 554 genes whose silencing affected MDP-induced IL-8 secretion in the primary screen. Final validated IL-8 regulators (positive or negative) are listed in the comments column. Reagent IDs not provided |